Oric Pharmaceuticals (ORIC)
$9.52
+0.19
(+2.04%)▲
Insights on Oric Pharmaceuticals
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 229.2% return, outperforming this stock by 290.2%
Performance
- $9.31$9.69$9.52
2.21%
Downside
Day's Volatility :3.87%
Upside
1.7%
- $4.90$16.65$9.52
48.53%
Downside
52 Weeks Volatility :70.57%
Upside
42.82%
Returns
| Period | Oric Pharmaceuticals | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -17.07% | -1.1% | 0.0% |
6 Months | 34.46% | 10.3% | 0.0% |
1 Year | 83.78% | 5.3% | 1.7% |
3 Years | -61.03% | 14.5% | -22.3% |
Highlights
Market Capitalization | 516.8M |
Book Value | $4.08 |
Earnings Per Share (EPS) | -1.96 |
Wall Street Target Price | 19.14 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -27.74% |
Return On Equity TTM | -45.11% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -109.7M |
Diluted Eps TTM | -1.96 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.83 |
EPS Estimate Next Year | -1.98 |
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Next Quarter | -0.51 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 101.05%
Technicals Summary
Sell
Neutral
Buy
Oric Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Oric Pharmaceuticals | -16.42% | 34.46% | 83.78% | -61.03% | -63.06% |
 Moderna, Inc. | 24.09% | 61.99% | -3.5% | -32.49% | 361.73% |
 Regeneron Pharmaceuticals, Inc. | -1.4% | 14.78% | 16.74% | 91.89% | 178.31% |
 Novo Nordisk A/s | -2.34% | 26.33% | 47.85% | 229.23% | 422.3% |
 Vertex Pharmaceuticals Incorporated | -2.12% | 6.37% | 15.53% | 83.6% | 130.15% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Oric Pharmaceuticals | NA | NA | NA | -1.83 | -0.45 | -0.28 | NA | 4.08 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Oric Pharmaceuticals | Buy | $516.8M | -63.06% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 361.73% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 178.31% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 422.3% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.15% | 28.81 | 36.68% |
Institutional Holdings
FMR Inc
10.39%Nextech Invest AG
6.36%Alkeon Capital Management, LLC
5.35%Column Group LLC
5.30%EcoR1 Capital, LLC
5.07%BlackRock Inc
4.59%
Corporate Announcements
Oric Pharmaceuticals Earnings
Oric Pharmaceuticals’s price-to-earnings ratio stands at None
Read More
Company Information
oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.
Organization | Oric Pharmaceuticals |
Employees | 100 |
CEO | Dr. Richard A. Heyman Ph.D. |
Industry | Health Technology |
